Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Dokkyo Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT02301806
- Locations
- 🇯🇵
Dokkyo Medical University, Mibu, Tochigo, Japan
Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2018-07-23
- Target Recruit Count
- 388
- Registration Number
- NCT02280486
- Locations
- 🇨🇳
at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
- Conditions
- Interventions
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 291
- Registration Number
- NCT02226003
Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02172261
Glycemic Durability After Metformin Failure
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 450
- Registration Number
- NCT02142309
- Locations
- 🇮🇹
Department of Geriatrics and Metabolic Diseases, Naples, Italy
🇮🇹Katherine Esposito, Naples, Italy
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 192
- Registration Number
- NCT02072096
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States
🇺🇸Carolina Health Specialists, Myrtle Beach, South Carolina, United States
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 464
- Registration Number
- NCT02036515
Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Qifu Li
- Target Recruit Count
- 40
- Registration Number
- NCT02026310
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing,, Chongqing, China
Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
- Conditions
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02007278
- Locations
- 🇨🇴
Novartis Investigative Site, Monteria, Colombia
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 461
- Registration Number
- NCT01958671
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.